Alpha-Aminobutyric Acid.
Research-backed amino acid with potential health benefits. May act as a weak calming agent in the brain, similar to its famous cousin, GABA. Some research points to a role in sleep and reducing nervous tension.
Reviewed March 2026
- Category
- Amino acid
What Alpha-Aminobutyric Acid is, and what it does.
- Does it work
- It suits people who follow amino acid metabolism closely and want the non-sulfur relative of cysteine. Human supplement trials are absent, so the ground here is biochemistry, not outcomes.
- How much to take
- Starts at 100-250mg before bed. Some formulas go up to 500mg. There's no established standard dose, so it's best to start low.
- Time to feel it
- Nobody has published a time course in people. Where it shows up is in plasma, as a marker of glutathione turnover, rather than in anything you would notice hour to hour.
- The first dose
- Probably nothing. If you're sensitive, maybe a slight feeling of relaxation within an hour or two. Don't count on it.
- With regular use
- The goal is more consistent unwinding and potentially easier sleep onset over weeks. No solid long-term data exists for supplementation.
- How well tolerated
- Appears well tolerated at common doses. It's not a well-studied supplement, so there's less safety data than for things like creatine or magnesium.
- How it feels
- Subtle, if anything. A gentle easing of tension, not a sedative. Think of it as turning down the background noise a single notch.
- The overlooked benefit
- Its main use so far is as a readout. Labs measure it, and the ophthalmic acid built from it, to track glutathione turnover and how much cysteine the body has to spare.
250 to 500mg a day is where Alpha-Aminobutyric Acid works.
Source: Biomarker research; limited supplementation data
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Alpha-Aminobutyric Acid is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Marker of glutathione turnover and cysteine availabilityCohort study
- Substrate for ophthalmic acid synthesis by glutamate-cysteine ligaseIn vitro study
- Plasma response to a methionine loadCohort study
- Association with markers of hepatic amino acid handlingCohort study
Questions people ask about Alpha-Aminobutyric Acid.
- Is this the same as GABA?
- No. It's a cousin. It might act on similar pathways in the brain, but it's a different molecule.
- Will it make me drowsy?
- Unlikely to be a strong sedative. More of a mild relaxant. Don't drive until you know how it affects you, just in case.
- Can I take it with other sleep aids?
- Check with your doctor first. Stacking calming supplements can have unpredictable effects.
- Is it better than L-Theanine?
- L-Theanine has way more research backing it for calm focus. Start there. This is a plan B or C.
- Why is it in my pre-workout?
- Some brands add it hoping to smooth out stimulant jitters. The evidence for this is very weak.
- Does it build tolerance?
- Unknown. Given the limited data, it's probably wise to cycle it—maybe 5 days on, 2 days off.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Glutamate cysteine ligase accepts 2-aminobutyrate in place of cysteine, producing gamma-glutamyl-2-aminobutyrate instead of the normal glutathione intermediate. The two amino acids therefore compete at the first committed step of glutathione synthesis.
Alpha-aminobutyrate is a substrate analogue of cysteine at glutamate cysteine ligase, so cysteine availability decides which product the enzyme makes. Ample cysteine keeps the enzyme on the glutathione route.
Glutathione synthetase adds glycine to the gamma-glutamyl dipeptide, and it does the same when 2-aminobutyrate has taken cysteine's place, yielding ophthalmate. Glycine supply is shared between the two products.
Rising 2-aminobutyrate and ophthalmate levels are used as readouts of accelerated glutathione turnover, because they appear when cysteine is being drawn down. The two move on the same axis rather than acting on each other.
Threonine catabolism yields 2-oxobutyrate, which is transaminated to 2-aminobutyrate. Threonine intake feeds the pool from the amino acid side.
Both the transamination that forms 2-aminobutyrate from 2-oxobutyrate and the cystathionine gamma-lyase step that releases that keto acid depend on pyridoxal 5-phosphate. B6 status therefore governs flux into and out of this pool.
Methionine passing through SAM and homocysteine into cystathionine releases 2-oxobutyrate when cystathionine is cleaved, which is the direct precursor of 2-aminobutyrate. Higher flow through that route raises the pool.
Alpha-aminobutyric acid is a by-product of methionine breakdown. Cystathionine gamma-lyase cleaves cystathionine into cysteine and alpha-ketobutyrate, and transamination of that keto acid gives alpha-aminobutyrate. A methionine load therefore raises circulating alpha-aminobutyric acid, which is why the amino acid is read as an index of transsulfuration flux rather than as an independent actor.
Serine is the carbon partner homocysteine condenses with, via cystathionine beta-synthase, to make cystathionine. Everything downstream, cysteine and alpha-aminobutyrate alike, depends on that step running. Serine availability therefore sits upstream of alpha-aminobutyrate production as a matter of settled pathway chemistry.
Both transsulfuration enzymes, cystathionine beta-synthase and cystathionine gamma-lyase, are pyridoxal-5-phosphate dependent, and the transaminase that converts alpha-ketobutyrate to alpha-aminobutyrate is also a P-5-P enzyme. Low B6 status slows the whole sequence. This is textbook cofactor dependence and needs no trial to state.
Homocysteine has two fates: remethylation to methionine, which needs methylcobalamin, or commitment to transsulfuration. When remethylation capacity is limited, more homocysteine goes down the transsulfuration branch that generates alpha-aminobutyrate. The relationship is a flux partition described by established pathway biochemistry, and any measured shift in plasma amino acids is a marker of that partition.
5-methyltetrahydrofolate is the methyl donor for methionine synthase, so folate status sets how much homocysteine is recycled rather than committed to the cysteine branch. Alpha-aminobutyrate output moves with that same partition. Established pathway wiring, not a tested combination.
Glutamate-cysteine ligase accepts alpha-aminobutyrate in place of cysteine, producing gamma-glutamyl-aminobutyrate and eventually ophthalmic acid instead of glutathione. Raising cysteine supply, which is what N-acetylcysteine does, shifts that competition back toward glutathione. The competition is well described in the enzymology literature; how much it matters at ordinary supplemental intakes has not been quantified in people.
Glutamine feeds the glutamate pool that glutamate-cysteine ligase uses as its first substrate, the same substrate consumed when the enzyme condenses alpha-aminobutyrate instead of cysteine. Adequate glutamate supply is therefore a precondition for either product forming. The link is pathway logic; no combination study is being claimed.
Cysteine leaving transsulfuration divides between glutathione synthesis, taurine synthesis and sulfate production. Alpha-aminobutyrate accumulation reports on how busy the upstream part of that pathway is. Supplying taurine directly removes one of the demands on cysteine, which is a plausible pathway-level interaction rather than a measured one.
Riboflavin becomes FAD, the cofactor glutathione reductase needs to regenerate reduced glutathione. That regeneration determines how much glutathione a cell has to spend, which is the context in which the ophthalmic acid to glutathione ratio is interpreted. Established cofactor chemistry one step removed from alpha-aminobutyrate itself.
Nothing specific on file for Alpha-Aminobutyric Acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Alpha-Aminobutyric Acid actually does.
Alpha-aminobutyric acid, also written 2-aminobutyric acid or AABA, is an amino acid your body never builds proteins from. It comes from alpha-ketobutyrate, which gets freed when cystathionine gamma-lyase splits cystathionine on the road from methionine to cysteine.
Picture alanine with one extra carbon in its side chain, or cysteine with the sulfur handle snapped off. No sulfhydryl group means it can't do any redox chemistry of its own.
Glutamate-cysteine ligase, the bottleneck enzyme for making glutathione, will take alpha-aminobutyrate in place of cysteine. What comes out is ophthalmic acid, gamma-glutamyl-aminobutyryl-glycine, a glutathione lookalike with no thiol on it.
Same enzymes as glutathione, but ophthalmic acid only piles up when cysteine runs short relative to what those enzymes could handle. So ophthalmic acid and alpha-aminobutyrate in blood and tissue get read as markers of glutathione turnover and cysteine supply. Markers of traffic through a pathway, not any clinical outcome.
Where Alpha-Aminobutyric Acid comes from.
There are two ways to make it. Bacteria fed sugar can build it, which gives the natural single-handed version straight away. Or chemists can build it from a small feedstock molecule, which produces a mix of both left and right handed versions that has to be separated if only one is wanted. The finished powder looks the same either way; the enantiomer line on the certificate is the tell.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
The microbial route starts from glucose fed to an engineered bacterial strain; the synthetic route starts from a short-chain aldehyde or nitrile intermediate.
Fermentation strains are selected or engineered to overflow the transsulfuration and threonine-deaminase branches that release alpha-ketobutyrate, which is transaminated to the amino acid. The chemical route builds the racemate by Strecker-type amination.
Cells and solids are removed by filtration; the amino acid stays in the aqueous phase and is captured on ion-exchange resin.
Elution from resin, decolourisation over carbon, then crystallisation from water or aqueous alcohol. A synthetic racemate needs a further resolution step if a single enantiomer is specified.
Dried, sieved and assayed for identity, enantiomeric ratio where relevant, and residual solvent.
Labels rarely say which route was used, and the strain, the fermentation feedstock and any resolution step are usually held as supplier confidential information.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
